Chemical Works of Gedeon Richter Plc (RGEDF)
37.77
-0.43
(-1.13%)
USD |
OTCM |
Jun 10, 16:00
Chemical Works of Gedeon Richter Enterprise Value : 5.985B for June 10, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 10, 2026 | 5.985B |
| June 09, 2026 | 6.064B |
| June 08, 2026 | 6.209B |
| June 05, 2026 | 6.146B |
| June 04, 2026 | 6.148B |
| June 03, 2026 | 6.179B |
| June 02, 2026 | 6.718B |
| June 01, 2026 | 6.633B |
| May 29, 2026 | 6.633B |
| May 28, 2026 | 6.616B |
| May 27, 2026 | 6.464B |
| May 26, 2026 | 6.218B |
| May 22, 2026 | 6.309B |
| May 21, 2026 | 6.458B |
| May 20, 2026 | 6.223B |
| May 19, 2026 | 6.429B |
| May 18, 2026 | 6.529B |
| May 15, 2026 | 6.345B |
| May 14, 2026 | 6.485B |
| May 13, 2026 | 6.368B |
| May 12, 2026 | 6.411B |
| May 11, 2026 | 6.865B |
| May 08, 2026 | 7.003B |
| May 07, 2026 | 6.800B |
| May 06, 2026 | 6.951B |
| Date | Value |
|---|---|
| May 05, 2026 | 6.570B |
| May 04, 2026 | 6.490B |
| May 01, 2026 | 7.005B |
| April 30, 2026 | 6.873B |
| April 29, 2026 | 6.692B |
| April 28, 2026 | 6.525B |
| April 27, 2026 | 6.874B |
| April 24, 2026 | 6.713B |
| April 23, 2026 | 6.713B |
| April 22, 2026 | 6.844B |
| April 21, 2026 | 6.768B |
| April 20, 2026 | 7.212B |
| April 17, 2026 | 7.354B |
| April 16, 2026 | 7.011B |
| April 15, 2026 | 6.940B |
| April 14, 2026 | 7.170B |
| April 13, 2026 | 6.469B |
| April 10, 2026 | 6.003B |
| April 09, 2026 | 5.803B |
| April 08, 2026 | 6.533B |
| April 07, 2026 | 5.787B |
| April 06, 2026 | 6.153B |
| April 02, 2026 | 4.750B |
| April 01, 2026 | 4.750B |
| March 31, 2026 | 4.750B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| AstraZeneca PLC | 581.37B |
| ANI Pharmaceuticals, Inc. | 2.161B |
| Corcept Therapeutics, Inc. | 8.056B |
| Assertio Holdings, Inc. | 120.08M |
| Veru, Inc. | 19.42M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 199.45M |
| Revenue (Quarterly) | 670.74M |
| Total Expenses (Quarterly) | 471.89M |
| EPS Diluted (Quarterly) | 1.090 |
| Gross Profit Margin (Quarterly) | 67.10% |
| Profit Margin (Quarterly) | 29.74% |
| Earnings Yield | 9.85% |
| Operating Earnings Yield | 13.80% |
| Normalized Earnings Yield | 9.851 |